Core Points - The company, 创胜集团-B (06628), announced the issuance of 200,000 reward shares to one reward grantee under its share incentive plan [1] - Additionally, the company granted 800,000 stock options to two option grantees under the same share incentive plan [1]

Group 1 - The company, 创胜集团-B (06628.HK), announced the grant of 200,000 reward shares to one reward grantee under its share incentive plan on November 20, 2025 [1] - Additionally, the company granted 800,000 stock options to two option grantees under the same share incentive plan [1]

根據上市規則第17.06A條，董事會宣佈，於2025年11月20日，本公司根據股份激 勵計劃向1名獎勵承授人授出200,000股獎勵股份（「11月獎勵授出」）及根據股份激 勵計劃向2名購股權承授人授出800,000份購股權（「11月購股權授出」）。 11月獎勵授出的詳情載列如下： 授出獎勵股份的購買價： 零 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 根據股份激勵計劃授出獎勵股份及購股權 股份於授出日期的收市價： 每股股份2.86港元 1 授出日期： 2025年11月20日 獎勵承授人人數： 1名服務提供商 授出獎勵股份數目： 200,000股獎勵股份（佔本公司截至本公告日期已 發行股本（不包括庫存股份）總額的約0.04%）授予 Marciniak先生，彼透過受聘為本公司顧問，從而成 為本公司的服務提供商，有 ...

Core Viewpoint - The chairman of the board, Qian Xueming, has increased his stake in Chuangsheng Group (06628) by purchasing 34,000 shares at a price of HKD 2.8581 per share, totaling approximately HKD 97,200, which indicates confidence in the company's future prospects [1] Summary by Category Shareholding Activity - Qian Xueming's recent purchase brings his total shareholding to 38 million shares, representing an ownership stake of 8.39% in Chuangsheng Group [1]

Core Viewpoint - The chairman of the board, Qian Xueming, increased his stake in Chuangsheng Group (06628) by purchasing 34,000 shares at a price of HKD 2.8581 per share, totaling approximately HKD 97,200, which indicates confidence in the company's future prospects [1] Summary by Category Shareholding Activity - Qian Xueming's recent purchase brings his total shareholding to 38 million shares, representing an ownership stake of 8.39% in Chuangsheng Group [1]

Core Viewpoint - The company announced the resignation of Deloitte as its auditor, effective from November 12, 2025, and appointed Ernst & Young as the new auditor to fill the vacancy until the next annual general meeting [1] Group 1 - Deloitte has resigned from its position as the company's auditor, effective November 12, 2025 [1] - The board of directors has resolved to appoint Ernst & Young as the new auditor based on the recommendation of the audit committee [1] - Ernst & Young will serve as the auditor until the conclusion of the company's next annual general meeting [1]

Core Viewpoint - The company announced the resignation of its auditor, Deloitte, effective November 12, 2025, and appointed Ernst & Young as the new auditor to fill the vacancy until the next annual general meeting [1] Group 1 - Deloitte has resigned from its position as the company's auditor [1] - The resignation will take effect on November 12, 2025 [1] - The board has decided to appoint Ernst & Young as the new auditor based on the recommendation of the audit committee [1] Group 2 - Ernst & Young will serve as the new auditor starting from November 12, 2025 [1] - The appointment of Ernst & Young will last until the conclusion of the company's next annual general meeting [1]

Core Viewpoint - The company has announced the resignation of its auditor, Deloitte, effective November 12, 2025, and has appointed Ernst & Young as the new auditor to fill the vacancy until the next annual general meeting [1] Group 1 - Deloitte has resigned as the company's auditor, with the resignation taking effect on November 12, 2025 [1] - The board has resolved to appoint Ernst & Young as the new auditor, effective from the same date [1] - Ernst & Young will serve until the conclusion of the company's next annual general meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：6628） 變更核數師 本公告由創勝集團醫藥有限公司（「本公司」）（連同其附屬公司，統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則第13.51(4)條作出。 核數師辭任 本公司董事（「董事」）會（「董事會」）宣佈，德勤• 關黃陳方會計師行（「德勤」）已辭 任本公司核數師職務，自2025年11月12日起生效，原因為本公司與德勤未能就審 核本集團截至2025年12月31日止財政年度之綜合財務報表之擬議審計費用達成共 識。 本公司審計委員會（「審計委員會」）已審閱德勤以及其他專業會計師事務所提出的 審核費用建議，並已審議彼等各自的經驗、資源分配及截至2025年12月31日止年 度的建議費用。鑒於其他專業會計事務所提出的建議更具競爭力，董事會在獲得 審計委員會的推薦建議後信納，更換 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 ...